Replies to post #130344 on Biotech Values

[DewDiligence]

I would guess that most of them are worthless and definitely not worth the cost of their prosecution. But the other side of that is if one of them blocks launch of a competing generic ala aL, then it pays for a lot of misses.

That’s how things typically work for technology companies in general, not just biotech.